Gastric Emptying - Implications for the Pathogenesis of Type 2 Diabetes

Sponsor
University of Nottingham (Other)
Overall Status
Recruiting
CT.gov ID
NCT03864562
Collaborator
University of Adelaide (Other)
60
1
46
1.3

Study Details

Study Description

Brief Summary

People of black African and Caribbean descent have a greater risk of developing type 2 diabetes than white Europeans. The aim of this study is to increase our knowledge of how the condition may arise, and what underlies this increased risk. Following a successful screening visit to confirm eligibility for the study, we will be investigating how quickly a glucose drink empties out of the stomach in 30 white Europeans and 30 people of black African or Caribbean descent. In addition, we will study the impact that gastric emptying rate has on blood glucose and satiety hormones released normally by the gut in response to eating. Blood and breath samples will be collected before and during an oral glucose tolerance test.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Background It is recognized that there are differences between ethnic groups in the risk of developing type 2 diabetes (T2D), but the underlying pathophysiology remains poorly defined. For example, whilst insulin resistance, exacerbated by obesity, is common in Caucasian, Hispanic and South Asian populations, impairment in insulin secretion appears to be the primary defect in the pathogenesis of T2D in East Asians. Within the United Kingdom (UK), diabetes and its complications disproportionately affect ethnic minority groups, particularly those of black African-Caribbean (AfC) descent. Studies indicate that the rate of gastric emptying is a major determinant of postprandial glycemia and insulinemia in those with a White European (WE) background in both health and T2D, and although there is evidence that gastric emptying is influenced by ethnicity (which may contribute to the development of T2D), gastric emptying has, to our knowledge, not been evaluated in those of AfC heritage.

    Aims The primary objective is to compare the gastric emptying rate in 2 UK ethnic groups. This will be done by conducting a descriptive, cross-sectional pilot study in 60 healthy participants. Secondary objectives are to determine any relationship between glycemia, insulinemia and incretin hormone secretion in these groups.

    Experimental protocol Sixty volunteers; 30 of WE and 30 of black AfC heritage will be recruited. Following a successful medical screening visit, participants will be asked to record their dietary intake over 3 days before attending the laboratory for their study visit. On the day before the study visit they will be asked to avoid strenuous exercise, alcohol and caffeine intake and to eat their normal diet. On the study day, participants will arrive at the laboratory in the morning following an overnight fast. A cannula will be inserted into a vein in the top of the hand and the hand placed in a warming box for repeat arterialized-venous blood sampling over the study day. After baseline breath and blood samples have been taken, participants will then be given a drink containing 75g of glucose dissolved in 300ml water (standard oral glucose tolerance test), to which has been added 150mg of 13C labelled acetate, and asked to consume it within 5 minutes. The stable isotope label on the acetate allows us to assess gastric emptying by detecting the appearance of 13CO2 in breath. Blood samples (6ml) will be collected prior to the drink, with further samples being taken every 15min for the first 2hrs, then every 30min for the next hour, with a final sample taken at 4hrs. Blood will be analysed for glucose, insulin, C-peptide, Glucagon-like peptide 1 (GLP-1), glucagon, and Gastric inhibitory polypeptide (GIP). Following the drink, subjects will also be asked to complete satiety and GI symptom questionnaires every half hour throughout the study. At the end of the 4 hours, participants will be asked to complete a series of autonomic function tests, during which we will measure blood pressure and heart rate. These tests are 2mins of rhythmic breathing (5sec inhale: 5sec exhale) and postural change to standing from resting semi-supine. After this time, the cannula will be removed and the study is completed

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Gastric Emptying in Non-diabetic Individuals With Black African/Caribbean Heritage - Implications for the Pathogenesis of Type 2 Diabetes
    Actual Study Start Date :
    Mar 1, 2019
    Anticipated Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Dec 30, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Black African or Caribbean

    Healthy individuals of black African or Caribbean descent

    White European

    Healthy individuals of white European descent

    Outcome Measures

    Primary Outcome Measures

    1. Gastric emptying rate [4 hours]

      Time for clearance of half of the glucose drink (measured via a stable isotope breath test and area under the incremental postprandial blood glucose response curve)

    Secondary Outcome Measures

    1. Serum Insulin concentration [4 hours]

      Serum Insulin response to the glucose drink, measured by serial blood sampling and later analysis using a radio-immuno assay (RIA)

    2. Whole blood glucose concentration [4 hours]

      Blood glucose response to the glucose drink, measured by serial blood sampling and immediate analysis using the glucose oxidase method

    3. Plasma glucagon concentration [4 hours]

      Plasma glucagon response to the glucose drink, measured by serial blood sampling and later analysis using an RIA

    4. Plasma GLP-1 concentration [4 hours]

      Plasma GLP-1 response to the glucose drink, measured by serial blood sampling and later analysis using an enzyme-linked immunosorbent assay (ELISA)

    5. Plasma GIP concentration [4 hours]

      Plasma GIP response to the glucose drink, measured by serial blood sampling and later analysis using an enzyme-linked immunosorbent assay (ELISA)

    6. Serum C-peptide concentration [4 hours]

      Serum C-peptide response to the glucose drink, measured by serial blood sampling and later analysis using an enzyme-linked immunosorbent assay (ELISA)

    7. Attrition rate [1 year]

      Number of participants completing the protocol as a proportion of those who were recruited to the study

    8. Recruitment rate [1 year]

      Number of people volunteering to take part in the study as a proportion of those expressing initial interest

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • White European or black African / Caribbean heritage

    • BMI >18 kg/m2

    • Ability to give written informed consent

    • English speaking

    Exclusion Criteria:
    • Any significant medical condition

    • Uncontrolled hypertension

    • Alcohol consumption >14 units / week

    • Random blood Glucose concentration above 7.8mmol/l

    • Hemoglobin A1c (HbA1c) >47mmol/mol (>6.4%)

    • Use of regular medication, (oral contraceptive pill or antihypertensive medication are acceptable if use has been for >6 months)

    • History of Irritable Bowel Syndrome, food intolerances or any gastrointestinal disorders

    • Previous bariatric surgery, or gastrointestinal surgery which may affect normal function (e.g. bowel resection)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 David Greenfield Human Physiology Unit, University of Nottingham Nottingham Notts United Kingdom NG72UH

    Sponsors and Collaborators

    • University of Nottingham
    • University of Adelaide

    Investigators

    • Study Director: Michael Horowitz, MD PhD, University of Adelaide

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Elizabeth Simpson, Senior Research Fellow, University of Nottingham
    ClinicalTrials.gov Identifier:
    NCT03864562
    Other Study ID Numbers:
    • 226-1901
    First Posted:
    Mar 6, 2019
    Last Update Posted:
    Apr 6, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Elizabeth Simpson, Senior Research Fellow, University of Nottingham
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2022